methyleneaminocarboxylic acid tert-butyl ester | 801290-71-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 炔丙基型1，3-偶极有机化合物
• 英文名称: methyleneaminocarboxylic acid tert-butyl ester
• 英文别名: methylidene tert-butyl carbamate；tert-butyl N-methylidenecarbamate
• CAS: 801290-71-1
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: WMBDDTUBUOEKTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyleneaminocarboxylic acid tert-butyl ester 在 溶剂黄146 、 锌 、 三氯氧磷 作用下， 以 乙醚 为溶剂， 反应 7.0h， 生成 1-Boc-3-氮杂环丁酮
  参考文献：
  名称：

  Ni环炔肟酯与内炔烃的Ni催化加氢烷基化反应合成三取代烯烃。

  摘要：

  提出了一种用环酮肟酯对内炔烃进行Ni催化加氢烷基化的方法。该反应具有广泛的底物范围。这种加氢烷基化显示出优异的区域选择性和立体选择性。该方法使得容易获得的起始原料可用于获得一定范围的氰基取代的单构型三取代的烯烃。这些是有价值的原料化学品，并广泛用于合成和药物化学中。

  DOI：

  10.1039/d0cc06517j
• 作为产物：
  描述：

  N-Boc-(甲苯磺酰)甲胺 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.08h， 生成 methyleneaminocarboxylic acid tert-butyl ester
  参考文献：
  名称：

  N -Boc-1-氨基烷基膦酸二乙酯的快速一锅法合成

  摘要：

  已经开发了N -Boc-1-氨基烷基膦酸二乙酯的一般的一锅式，无提纯的合成方法。该方法包括在氢化氢对四氢呋喃中的α-酰胺基烷基-对甲苯砜的作用下，将碱式亚磷酸二乙酯钠的Michael催化加成到N- Boc亚胺中。

  DOI：

  10.1016/s0040-4039(01)02289-4

文献信息

• [EN] SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE<br/>[FR] DÉRIVÉS SUBSTITUÉS DE MONO- ET POLYAZANAPHTHALÈNE ET LEUR UTILISATION
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2016128465A1

  公开（公告）日：2016-08-18

  Disclosed are compounds of formula (I) wherein A is CH or N, B is CR or N; and D is CR; R represents hydrogen, OH or NH2; R1 and R2, independently of each other, represent hydrogen, N(R3)2, halogen, cyano, nitro, R4-C1-C4alkyl, R4-C1-C4halogenoalkyl, OH, R4-C1-C4alkoxy, R4-C1-C4halogenoalkoxy, SH, R4-C1-C4alkythio, R4-C1-C4halogenoalkylthio; R3 represents, independently at each occurrence, hydrogen, R4-C1-C4alkyl or R4-C1-C4halogenoalkyl; R3a represents, independently at each occurrence, hydrogen or C1-C4 alkyl; R4 represents, independently at each occurrence, hydrogen, halogen, cyano, OH, SH, NH2, NH(CH3) or N(CH3)2; X represents a group of formula –E- or –E-F-, wherein E and F are different from each other and represent a group selected from –C(R3a)2-, -(C=O)-, -NR3a- and -O- and F is linked to Y, with the proviso that if X represents –E-F- one of E or F represents –C(R3a)2- or -(C=O)-; Y represents a group selected from C1-C6alkyl, mono- or bicyclic C3-C11cycloalkyl, which may be partially unsaturated, mono- or bicyclic 3 to 11-membered heterocycloalkyl, which may be partially unsaturated, a mono- or bicyclic group comprising at least one aryl or heteroaryl cycle, wherein said heterocycloalkyl group and said group comprising at least one heteroaryl cycle comprise one or more heteroatoms selected from nitrogen, oxygen and sulfur and said group Y is either unsubstituted or substituted by one or more substituents and comprises including its substituents one or more than one nitrogen atom having a lone electron pair; and Z represents a mono- or bicyclic group comprising at least one aryl or heteroaryl cycle, said heteroaryl cycle comprising one or more heteroatoms selected from nitrogen, oxygen and sulfur, which aryl or heteroaryl group is unsubstituted or substituted by one or more substituents; including tautomers of said compounds, mixtures of two tautomeric forms of said compounds, and pharmaceutically acceptable salts of said compounds, tautomers thereof or mixtures of two tautomeric forms thereof, preferably with the proviso that Y comprises one or more primary amino group -NH2, when X represents -(C=O)- or –(C=O)-NR3a-, wherein R3a represents hydrogen or C1-C4alkyl; which are useful for the treatment of proliferation disorders or diseases, such as cancer.

  公开的是以下式(I)的化合物，其中A为CH或N，B为CR或N；D为CR；R代表氢、OH或NH2；R1和R2彼此独立地代表氢、N(R3)2、卤素、氰基、硝基、R4-C1-C4烷基、R4-C1-C4卤代烷基、OH、R4-C1-C4烷氧基、R4-C1-C4卤代烷氧基、SH、R4-C1-C4硫代烷基、R4-C1-C4卤代硫代烷基；R3在每次出现时独立地代表氢、R4-C1-C4烷基或R4-C1-C4卤代烷基；R3a在每次出现时独立地代表氢或C1-C4烷基；R4在每次出现时独立地代表氢、卤素、氰基、OH、SH、NH2、NH(CH3)或N(CH3)2；X代表式-E-或-E-F-的基团，其中E和F彼此不同且代表从-C(R3a)2-、-(C=O)-、-NR3a-和-O中选择的基团，F与Y连接，但如果X代表-E-F-，则E或F中的一个代表-C(R3a)2-或-(C=O)-；Y代表从C1-C6烷基、单环或双环C3-C11环烷基（可能部分不饱和）、单环或双环3至11成员杂环烷基（可能部分不饱和）、包含至少一个芳基或杂芳基环的单环或双环基团，其中所述杂环烷基基团和包含至少一个杂芳基环的基团包含从氮、氧和硫中选择的一个或多个杂原子，所述基团Y未取代或被一个或多个取代基取代，包括其取代基中的一个或多个具有孤对电子的氮原子；Z代表包含至少一个芳基或杂芳基环的单环或双环基团，所述杂芳基环包含从氮、氧和硫中选择的一个或多个杂原子，该芳基或杂芳基基团未取代或被一个或多个取代基取代；包括所述化合物的互变异构体、所述化合物的两种互变异构体形式的混合物，以及所述化合物、其互变异构体或其两种互变异构体形式的药学上可接受的盐，其中Y包括一个或多个一级氨基-NH2，当X代表-(C=O)-或-(C=O)-NR3a-时，其中R3a代表氢或C1-C4烷基；这些化合物对于治疗增殖性疾病或疾病，如癌症，是有用的。
• PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS
  申请人：RESPIVERT LIMITED

  公开号：US20150203475A1

  公开（公告）日：2015-07-23

  Compounds of formula (I): wherein R 1 , R 2 , J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.

  式(I)的化合物： 其中R1、R2、J、Q、V、X、Y和Z的定义如本文所述。这些化合物是p38丝裂原活化蛋白激酶酶家族（以下简称为p38 MAP激酶抑制剂）的抑制剂，特别是其α亚型，以及Syk激酶和Src酪氨酸激酶家族的抑制剂。这些化合物可用于治疗，包括在药物组合中，特别是用于治疗炎症性疾病，特别是肺部的炎症性疾病，如哮喘和COPD，以及胃肠道的炎症性疾病，如溃疡性结肠炎和克罗恩病，以及眼部的炎症性疾病，如葡萄膜炎。
• [EN] METAL-CATALYZED COUPLING OF ARYL AND VINYL HALIDES WITH ALPHA, ALPHA-DIFLUOROCARBONYL COMPOUNDS<br/>[FR] COUPLAGE CATALYSÉ MÉTALLIQUE D'HALOGÉNURES D'ARYLE ET DE VINYLE AVEC DES COMPOSÉS ALPHA, ALPHA-DIFLUOROCARBONYLE
  申请人：UNIV CALIFORNIA

  公开号：WO2014165861A1

  公开（公告）日：2014-10-09

  The coupling of aryl, heteroaryl, and vinyl halides with α,α-difluoroketones or silyl ethers or siylenol ethers of α,α-difluoroketones and α,α-difluoroamides and esters are described. Further derivatization of the coupling products (such as ketone cleavage and Baeyer-Villiger oxidation) is also described.

  描述了芳基、杂环基和乙烯卤化物与α，α-二氟酮或硅醚或α，α-二氟酮的硅醚或硅烯醇醚和α，α-二氟酮和α，α-二氟酰胺和酯的偶联。还描述了对偶联产物的进一步衍生化（如酮裂解和巴耶-维利格氧化）。
• [EN] QUINOLIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOLIN-2-ONE
  申请人：MERCK PATENT GMBH

  公开号：WO2017121444A1

  公开（公告）日：2017-07-20

  Compounds of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

  式(I)中X1、X2、X3、X4、R1、R2、R3、Q和Y的含义如权利要求书中所示，是c-Kit激酶的抑制剂，可用于癌症的治疗。
• HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：HECKEL Armin

  公开号：US20150011535A1

  公开（公告）日：2015-01-08

  The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  本发明涉及通式（I）的化合物，以及其互变异构体和盐，特别是其与无机或有机酸和碱形成的药用可接受盐，具有有价值的药理学特性，特别是对上皮钠通道具有抑制作用，并且用于治疗疾病，特别是肺部和气道疾病。